These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 24118885)
1. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Denison H; Nilsson C; Löfgren L; Himmelmann A; Mårtensson G; Knutsson M; Al-Shurbaji A; Tornqvist H; Eriksson JW Diabetes Obes Metab; 2014 Apr; 16(4):334-43. PubMed ID: 24118885 [TBL] [Abstract][Full Text] [Related]
2. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Denison H; Nilsson C; Kujacic M; Löfgren L; Karlsson C; Knutsson M; Eriksson JW Diabetes Obes Metab; 2013 Feb; 15(2):136-43. PubMed ID: 22950654 [TBL] [Abstract][Full Text] [Related]
3. Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol. Morentin Gutierrez P; Yates J; Nilsson C; Birtles S Pharmacol Res Perspect; 2019 Apr; 7(2):e00465. PubMed ID: 30899516 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse. Floettmann E; Lees D; Seeliger F; Jones HB Toxicol Pathol; 2015 Apr; 43(3):376-83. PubMed ID: 25112279 [TBL] [Abstract][Full Text] [Related]
5. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653 [TBL] [Abstract][Full Text] [Related]
6. Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release. Lin HV; Chen D; Shen Z; Zhu L; Ouyang X; Vongs A; Kan Y; Levorse JM; Kowalik EJ; Szeto DM; Yao X; Xiao J; Chen S; Liu J; Garcia-Calvo M; Shin MK; Pinto S PLoS One; 2013; 8(1):e54480. PubMed ID: 23336002 [TBL] [Abstract][Full Text] [Related]
13. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). Barlind JG; Bauer UA; Birch AM; Birtles S; Buckett LK; Butlin RJ; Davies RD; Eriksson JW; Hammond CD; Hovland R; Johannesson P; Johansson MJ; Kemmitt PD; Lindmark BT; Morentin Gutierrez P; Noeske TA; Nordin A; O'Donnell CJ; Petersson AU; Redzic A; Turnbull AV; Vinblad J J Med Chem; 2012 Dec; 55(23):10610-29. PubMed ID: 23116186 [TBL] [Abstract][Full Text] [Related]
14. Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice. Takemoto K; Fukasaka Y; Yoshimoto R; Nambu H; Yukioka H Physiol Rep; 2020 Aug; 8(15):e14542. PubMed ID: 32786057 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion. Maciejewski BS; Manion TB; Steppan CM World J Gastrointest Pathophysiol; 2017 Nov; 8(4):161-175. PubMed ID: 29184702 [TBL] [Abstract][Full Text] [Related]
16. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Vazquez Roque MI; Camilleri M; Stephens DA; Jensen MD; Burton DD; Baxter KL; Zinsmeister AR Gastroenterology; 2006 Dec; 131(6):1717-24. PubMed ID: 17087952 [TBL] [Abstract][Full Text] [Related]
17. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Acosta A; Camilleri M; Shin A; Vazquez-Roque MI; Iturrino J; Burton D; O'Neill J; Eckert D; Zinsmeister AR Gastroenterology; 2015 Mar; 148(3):537-546.e4. PubMed ID: 25486131 [TBL] [Abstract][Full Text] [Related]
18. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069 [TBL] [Abstract][Full Text] [Related]
19. How to fight obesity with antidiabetic drugs: targeting gut or kidney? Baretić M; Troskot R Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984 [TBL] [Abstract][Full Text] [Related]
20. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]